stockrowAdaptive Biotechnologies Corporation
ADPT Healthcare Diagnostics & Research
Adaptive Biotechnologies Corporation’s revenue for fiscal 2025 (year ended December 2025) was $277.0 million, up 54.8% from fiscal 2024.
- Revenue
- −10.7%
- EPS
- −66.7%
- Free cash flow
- +201.9%
Quarter to September 2026, against a year earlier
Follow ADPT
Alert me
Adaptive Biotechnologies Corporation (ADPT) EPS (diluted)
Adaptive Biotechnologies Corporation's EPS (diluted) for fiscal 2025 was −$0.39, compared with −$1.08 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$0.45. Over the past ten years it has ranged from −$3.68 (fiscal 2018) to −$0.39 (fiscal 2025) — the current reading is the highest in ten years. Adaptive Biotechnologies Corporation ranks 27th of 49 Diagnostics & Research companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$0.39 | — |
| FY2024 | −$1.08 | — |
| FY2023 | −$1.56 | — |
| FY2022 | −$1.40 | — |
| FY2021 | −$1.48 | — |
| FY2020 | −$1.11 | — |
| FY2019 | −$1.01 | — |
| FY2018 | −$3.68 | — |
| FY2017 | −$3.51 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.02 | — |
| Jun 2026 | −$0.25 | — |
| Mar 2026 | −$0.13 | — |
| Dec 2025 | −$0.09 | — |
| 29 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| CDNA CareDx, Inc. compare | $2.39 |
| VCYT Veracyte, Inc. compare | $1.55 |
| BLLN BillionToOne, Inc. compare | $0.92 |
| SHC Sotera Health Company compare | $0.60 |
| NEO NeoGenomics, Inc. compare | −$0.25 |
| RDNT RadNet, Inc. compare | −$0.27 |
| ADPT Adaptive Biotechnologies Corporation | −$0.45 |
| WGS GeneDx Holdings Corp. compare | −$3.64 |
| GRAL GRAIL, Inc. compare | −$9.50 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on ADPT
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement